Commentary: FDA Must Overcome Skepticism Toward Health Claims
This article was originally published in The Tan Sheet
In a guest commentary, regulatory and safety consultant George Burdock discusses his views on the historical developments that shaped FDA’s attitudes toward health claims, and what the agency could do to incentivize greater investment in this area by food and dietary supplement companies.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.